These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31903008)

  • 1. Cost-Effectiveness Analysis of Oral Anticoagulants in Stroke Prevention among Patients with Atrial Fibrillation in Taiwan.
    Liao CT; Lee MC; Chen ZC; Ku LE; Wang JD; Toh HS
    Acta Cardiol Sin; 2020 Jan; 36(1):50-61. PubMed ID: 31903008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.
    Liu CY; Chen HC
    Clin Drug Investig; 2017 Mar; 37(3):285-293. PubMed ID: 27988835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China.
    Zhou H; Nie X; Jiang M; Dong W
    J Clin Pharm Ther; 2022 Apr; 47(4):523-530. PubMed ID: 34783090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation.
    Dilokthornsakul P; Nathisuwan S; Krittayaphong R; Chutinet A; Permsuwan U
    Heart Lung Circ; 2020 Mar; 29(3):390-400. PubMed ID: 31000364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
    Shah A; Shewale A; Hayes CJ; Martin BC
    Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
    Hospodar AR; Smith KJ; Zhang Y; Hernandez I
    Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
    Harrington AR; Armstrong EP; Nolan PE; Malone DC
    Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
    Escobar Cervantes C; Martí-Almor J; Cabeza AIP; Bowrin K; Llorac Moix A; Genís Gironès M; Gasche D; Millier A; Tardu J; Toumi M; Briere JB
    PLoS One; 2022; 17(4):e0266658. PubMed ID: 35443000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding.
    Rattanachotphanit T; Limwattananon C; Waleekhachonloet O; Limwattananon P; Sawanyawisuth K
    Pharmacoeconomics; 2019 Feb; 37(2):279-289. PubMed ID: 30387074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada.
    Hafeez A; Cipriano LE; Kim RB; Zaric GS; Schwarz UI; Sarma S
    Pharmacoeconomics; 2024 Jan; 42(1):69-90. PubMed ID: 37596504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
    Rudakova AV; Tatarskiĭ BA
    Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation in Hong Kong.
    Peng K; Li Y; Chan EW; Wong ICK; Li X
    Value Health Reg Issues; 2023 Jul; 36():51-57. PubMed ID: 37030031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for Stroke Prevention in Patients with New-Onset Atrial Fibrillation.
    Micieli A; Wijeysundera HC; Qiu F; Atzema CL; Singh SM
    Med Decis Making; 2016 Apr; 36(3):366-74. PubMed ID: 26139448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.
    Lee SR; Choi EK; Kwon S; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH
    Stroke; 2019 Aug; 50(8):2245-2249. PubMed ID: 31208303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
    Janzic A; Kos M
    Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles.
    Wang CY; Pham PN; Thai TN; Brown JD
    Pharmacoeconomics; 2020 Dec; 38(12):1333-1343. PubMed ID: 32924092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.